Get the Daily Brief
Latest Biotech News
CRISPR CAR-T shutdown at Caribou after capital shortfall
Caribou Biosciences moved to discontinue its donor-derived CAR-T programs, saying it cannot raise enough capital to fund a late-stage path. The decision covers vispa-cel for relapsed or refractory...
Shionogi buys IntraBio to expand rare-disease portfolio
Shionogi agreed to acquire IntraBio for $2 billion, aiming to add late-stage and commercially validated rare-disease assets to its pipeline. IntraBio’s lead product, Aqneursa (levacetylleucine),...
Phase 3 setbacks for ArriVent lung cancer drug
ArriVent BioPharma said its lead investigational lung cancer therapy furmonertinib failed its primary goal in a late-stage Phase 3 trial. The drug was evaluated as a first-line monotherapy in...
First-line lymphoma win for Epkinly in Phase 3
AbbVie and Genmab reported that Epkinly, their T-cell engager bispecific, cut the risk of disease progression or death by nearly half when combined with R-CHOP in newly diagnosed diffuse large...
HHS launches SURPASS to accelerate adaptive clinical trial design
The U.S. Department of Health and Human Services launched the SURPASS program, an effort led by ARPA-H to redesign how seamless clinical trials are planned and run. Officials described the...
GE HealthCare to acquire Sofie Biosciences to expand PET radiopharmaceutical manufacturing
GE HealthCare agreed to buy Sofie Biosciences for $945 million in cash to expand U.S. radiopharmaceutical manufacturing capacity, particularly for time-sensitive PET products. The deal is expected...
Living Pharmas: controllers that keep drug levels on target in the brain
Researchers demonstrated an adaptive feedback controller that measures drug concentrations in the living brain in real time, learns pharmacokinetics per subject on the fly, and holds drug levels...
RougeTx raises $58M to develop oral small molecule for HHT
Dutch biotech RougeTx raised $58 million in a Series A to advance an oral small-molecule program for hereditary hemorrhagic telangiectasia (HHT). The company’s strategy centers on reattaching...
Forbion expands biotech VC with €2.3B across two new funds
Forbion, the Netherlands-based life sciences investor, raised €2.3 billion for two new venture funds, the firm’s largest fundraising to date. The capital is expected to back roughly 30 companies...
ArriVent, approvals, and policy signals converge on cancer and pricing
Beyond company-specific pipeline moves, the feed highlighted U.S. policy momentum around pricing transparency and federal priorities tied to clinical development. A separate report said the Trump...
FDA approval and label expansion for CLL first-line therapy
The FDA approved pirtobrutinib (Jaypirca) for adults with previously untreated CLL or SLL without del(17p), based on results from the phase 3 BRUIN CLL-313 trial. The study compared pirtobrutinib...
Caribou pulls back on allogeneic CAR-T programs amid financing pressure
Caribou Biosciences said it is exploring strategic alternatives and will discontinue further development of its two donor-derived allogeneic CAR-T programs: vispa-cel for relapsed or refractory...
Shionogi expands rare-disease portfolio with IntraBio acquisition
Shionogi agreed to acquire IntraBio for $2 billion to expand its rare-disease portfolio with Aqneursa (levacetylleucine), an FDA-approved therapy for the neurological manifestations of...
Epkinly wins first-line DLBCL phase 3 and sets up a Roche head-to-head
AbbVie and Genmab said Epkinly, their T-cell engager bispecific with standard chemotherapy, cut the risk of disease progression or death by nearly half in a phase 3 trial in newly diagnosed...
FDA fast-track pilot aims to reduce IND bottlenecks for clinical entry
The FDA launched an expedited investigational new drug (IND) pilot program intended to reduce time spent in early submissions and to apply more risk-proportionate, phase-appropriate judgment...
HHS launches SURPASS to use digital twins and adaptive controls for faster seamless trials
The U.S. Department of Health and Human Services launched SURPASS, a simulation-augmented, real-time platform for adapted seamless trials, aimed at transforming how clinical studies are designed...
GE HealthCare buys Sofie Biosciences to expand U.S. radiopharmaceutical manufacturing
GE HealthCare agreed to acquire Sofie Biosciences for $945 million in cash to expand its U.S. manufacturing footprint in PET radiopharmaceuticals. Sofie is a contract manufacturing organization...
Carcinoma immune evasion biology highlighted by SPP1 as a tumor “master switch”
A new review reports that the matrix protein SPP1 (osteopontin) orchestrates immunosuppression across the tumor microenvironment and lays out emerging strategies to target it. The synthesis...
Engineering safer, earlier diagnoses with AI on imaging for gastric and prostate cancer
Two separate imaging AI studies point toward noninvasive risk stratification before surgery. In gastric cancer, researchers in Guangzhou built a machine-learning model combining MRI radiomics and...
Drug discovery platform funding: Sensible Biotechnologies secures $47M for naturally modified mRNA
Sensible Biotechnologies raised $47 million to advance and scale its integrated mRNA technology platform, including a Series A and up to $20 million in non-dilutive funding from the Government of...